8-K - NIKA - Equibles

SECURITIES AND EXCHANGE

COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) of the SECURITIESEXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 9, 2024 (October 2, 2024)

NIKA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

colorado	000-56234	90-0292940
(State or other jurisdiction of Nika Pharmaceuticals,<br> Inc.)	(Commission File Number)	(IRS Employer Identification<br>No.)

2269 Merrimack Valley AvenueHenderson, NV 89044(Address

of principal executive offices) (Zip code)

(702)-326-3615Registrant's telephone number, including area

code:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Section 4 - Matters Related to Accountants and FinancialStatements

Item 4.01 Changes in Registrant’s Certifying Accountant.

On October 2, 2024, Nika Pharmaceuticals, Inc. made a discovery, which led it to consider that it is in the best interest not to continue its engagement of independent accountant OLAYINKA OYEBOLA & CO (Chartered Accountants). No services had been performed by OLAYINKA OYEBOLA & CO (Chartered Accountants) prior to the termination of the engagement on October 2, 2024.

On October 5, 2024, Nika Pharmaceuticals, Inc. engaged the firm of Boladale Lawal & Co (Chartered Accountants) to serve as the independent accountant to audit the company’s financial statements.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

23.1	Nika Pharmaceuticals Accountants) Inc.<br> Dismissal Consent by OLAYINKA OYEBOLA & CO (Chartered Accountants)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.

	NIKA PHARMACEUTICALS, INC.
Dated: October 9, 2024	By:	/s/ Dimitar Slavchev Savov
		Dimitar Slavchev Savov
		Chief Executive Officer,
		Director

NIKA PHARMACEUTICALS, INC.: Exhibit 23-1 - Filed by EDGARhub LLC

October 16, 2024

United States Securities and Exchange Commission Office of the Chief Accountant 100 F Street, N.E. Washington, D.C. 20549

Re: Nika Pharmaceuticals, Inc.

Dear Sirs/Madams,

We have read the statements under item 4.01 in Form 8-K dated October 9, 2024, of Nika Pharmaceuticals, Inc. to be filed with the Securities and Exchange Commission and we agree with such statements therein as related to our firm.

Regards,

Yours faithfully, For: Olayinka Oyebola & Co

Yinka Oyebola FCA Managing Partner/CEO